Literature DB >> 17400922

Crystal structure of the human ephrin-A5 ectodomain.

Dimitar Nikolov1, Chen Li, Martin Lackmann, Philip Jeffrey, Juha Himanen.   

Abstract

The Eph receptors, the largest subfamily of receptor tyrosine kinases, and their ephrin ligands are important mediators of cell-cell communication regulating cell attachment, pathfinding, and mobility in the nervous and cardiovascular systems. Recent structural studies have revealed unique molecular features that explain many of the biochemical and signaling properties of Ephs and ephrins. Nevertheless, open questions remain, including understanding the precise molecular mechanism underlining their binding-partner preferences and subclass specificity. In this study, we have determined and present the crystal structure of the extracellular domain of ephrin-A5-the first structure of an unbound A-class ephrin. The structure, determined at 2.1 A resolution, is a variation of the Greek key beta-barrel folding topology, containing eight beta-strands, and stabilized by two disulphide bonds. Overall, ephrin-A5 is structurally very similar to ephrin-B1 and ephrin-B2 but, unlike ephrin-B2, it does not show dimerization either in solution or in the crystals. Comparing free ephrin-A5 to the previously published structure of EphB2-bound ephrin-A5 reveals that significant conformational changes occur only around the G-H ephrin loop that upon binding bends toward the receptor. Interestingly, the G-H loop undergoes a very similar conformational rearrangement in ephrin-B2 upon receptor binding. The results of this study further emphasize the importance of the G-H loop for receptor recognition and selectivity, and could serve as a starting point for the development of structure-based Eph antagonists.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400922      PMCID: PMC2206647          DOI: 10.1110/ps.062665807

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  22 in total

1.  Topographic targeting and pathfinding errors of retinal axons following overexpression of ephrinA ligands on retinal ganglion cell axons.

Authors:  D Dütting; C Handwerker; U Drescher
Journal:  Dev Biol       Date:  1999-12-01       Impact factor: 3.582

2.  Crystal structure of an ephrin ectodomain.

Authors:  J Toth; T Cutforth; A D Gelinas; K A Bethoney; J Bard; C J Harrison
Journal:  Dev Cell       Date:  2001-07       Impact factor: 12.270

3.  Crystal structure of an Eph receptor-ephrin complex.

Authors:  J P Himanen; K R Rajashankar; M Lackmann; C A Cowan; M Henkemeyer; D B Nikolov
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

Review 4.  Mechanisms and functions of Eph and ephrin signalling.

Authors:  Klas Kullander; Rüdiger Klein
Journal:  Nat Rev Mol Cell Biol       Date:  2002-07       Impact factor: 94.444

Review 5.  Eph signaling: a structural view.

Authors:  Juha-Pekka Himanen; Dimitar B Nikolov
Journal:  Trends Neurosci       Date:  2003-01       Impact factor: 13.837

6.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

Review 7.  The ephrins and Eph receptors in angiogenesis.

Authors:  Nikki Cheng; Dana M Brantley; Jin Chen
Journal:  Cytokine Growth Factor Rev       Date:  2002-02       Impact factor: 7.638

8.  Crystallography & NMR system: A new software suite for macromolecular structure determination.

Authors:  A T Brünger; P D Adams; G M Clore; W L DeLano; P Gros; R W Grosse-Kunstleve; J S Jiang; J Kuszewski; M Nilges; N S Pannu; R J Read; L M Rice; T Simonson; G L Warren
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-09-01

9.  The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals.

Authors:  C A Cowan; M Henkemeyer
Journal:  Nature       Date:  2001-09-13       Impact factor: 49.962

10.  Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.

Authors:  Nicole K Noren; Mark Lu; Andrew L Freeman; Mitchell Koolpe; Elena B Pasquale
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

View more
  7 in total

1.  Structure of the ligand-binding domain of the EphB2 receptor at 2 A resolution.

Authors:  Yehuda Goldgur; Sari Paavilainen; Dimitar Nikolov; J P Himanen
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-01-31

Review 2.  Cell-cell signaling via Eph receptors and ephrins.

Authors:  Juha-Pekka Himanen; Nayanendu Saha; Dimitar B Nikolov
Journal:  Curr Opin Cell Biol       Date:  2007-10-24       Impact factor: 8.382

Review 3.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

4.  An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly.

Authors:  Elena Seiradake; Karl Harlos; Geoff Sutton; A Radu Aricescu; E Yvonne Jones
Journal:  Nat Struct Mol Biol       Date:  2010-03-14       Impact factor: 15.369

Review 5.  Cells under siege: viral glycoprotein interactions at the cell surface.

Authors:  Thomas A Bowden; E Yvonne Jones; David I Stuart
Journal:  J Struct Biol       Date:  2011-03-31       Impact factor: 2.867

6.  Epha3 acts as proangiogenic factor in multiple myeloma.

Authors:  Antonella Caivano; Francesco La Rocca; Ilaria Laurenzana; Tiziana Annese; Roberto Tamma; Ubaldo Famigliari; Vittorio Simeon; Stefania Trino; Luciana De Luca; Oreste Villani; Simona Berardi; Antonio Basile; Angelo Vacca; Giuseppe Saglio; Luigi Del Vecchio; Pellegrino Musto; Daniela Cilloni
Journal:  Oncotarget       Date:  2017-05-23

7.  The first identification of complete Eph-ephrin signalling in ctenophores and sponges reveals a role for neofunctionalization in the emergence of signalling domains.

Authors:  Arunkumar Krishnan; Bernard M Degnan; Sandie M Degnan
Journal:  BMC Evol Biol       Date:  2019-04-25       Impact factor: 3.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.